Retrospective case series reveals treatment outcomes with lecanemab in early Alzheimer's disease, indicating real-world effectiveness.
To report real-world data on patients with early Alzheimer’s disease (AD) treated with lecanemab in our geriatric clinical practice.
No takes yet. Share an insight, caveat, or question.
Margarita Reyes (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: